NBTX stock forecast, quote, news & analysis
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients... Show more
Why Nanobiotix S.A. (NBTX) Is Up +14% in the Last 30 Days
Key Takeaways
- NBTX stock rose approximately +14% over the past 30 days, driven by positive Phase 2 data from the CONVERGE study on JNJ-1900 (NBTXR3) in lung cancer and multiple analyst price target increases.
- Over the past quarter, the stock surged +62%, fueled by clinical progress, J&J partnership advancements, and financial updates extending cash runway.
- Key catalysts include early efficacy signals in oncology trials, analyst upgrades from firms like Guggenheim and UBS, and sector sentiment in biotechnology.
- Improved financial position with reduced net loss and non-dilutive financing supports ongoing development.
- Broader market trends in cancer therapeutics and radiotherapy enhancements bolstered investor confidence.
Nanobiotix S.A. (NBTX) Company Overview and Market Position
Nanobiotix S.A. is a late-stage clinical biotechnology company headquartered in Paris, France, specializing in physics-based nanotherapeutics to improve cancer treatment outcomes. Its lead candidate, NBTXR3 (also known as JNJ-1900 under a global licensing agreement with Janssen Pharmaceutica NV, part of Johnson & Johnson), is a radioenhancer composed of hafnium oxide nanoparticles designed to amplify radiotherapy effects on tumors while sparing healthy tissue. The company targets solid tumors like head and neck cancer, lung cancer, and others through partnerships and sponsored trials.
Nanobiotix's business model relies on licensing its nanotechnology platforms, including Nanoradioenhancer and Nanoprimer, to larger pharma partners for co-development and commercialization. This exposure to high-unmet-need oncology areas, combined with recent regulatory reclassifications and trial advancements, underpins its stock's sensitivity to clinical data and partnership milestones, explaining much of the recent price momentum in a volatile biotech sector.
Nanobiotix S.A. (NBTX) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, NBTX stock climbed from around $30.81 to $35.12, marking a +14% gain. The movement was trend-driven with moderate volatility, peaking near $36 amid news flow before stabilizing.
For the past quarter, the stock advanced from approximately $21.73 to $35.12, delivering a robust +62% increase. This period featured sharp rallies tied to specific catalysts, with a 52-week range of $3.26 to $41.89 highlighting its high-beta nature in biotech stock analysis.
What Drove NBTX Stock Price in the Last 30 Days
The primary catalyst was the March 30 announcement of initial Phase 2 CONVERGE study data, sponsored by Johnson & Johnson, evaluating JNJ-1900 (NBTXR3) in stage 3 inoperable non-small cell lung cancer (NSCLC). Early results in seven patients showed a 71.4% objective response rate (ORR) and 100% disease control rate (DCR), exceeding benchmarks of 45-50% ORR, with an acceptable safety profile. This fueled optimism for the program's broad potential across solid tumors.
Analyst reactions amplified the move: UBS raised its price target to $30 from $3.50 (Neutral); Guggenheim to $36 from $26 (Buy); H.C. Wainwright to EUR 34 from EUR 32; and Leerink to $37 from $26 (Outperform). These upgrades reflected higher success probabilities for NSCLC and head-and-neck programs.
Preclinical data on April 20 for Nanoprimer technology, enhancing LNP-delivered DNA immunotherapy, added to positive sentiment. Sector trends in oncology innovation supported the steady uptrend in price movement.
What Drove NBTX Stock Performance Over the Last Quarter
The quarter's +62% rally built on sustained narratives around the J&J partnership. Key was the full-year 2025 results on March 31, reporting €32.6M revenue (up from negative €7.2M), a narrowed €24M net loss (from €68.1M), and cash runway to early 2028 via a $71M non-dilutive royalty deal ($50M received) and licensing amendments reducing NANORAY-312 funding obligations.
Progress in lead programs—NANORAY-312 (head-and-neck cancer Phase 3) sponsorship transfer to J&J and CONVERGE first dosing/data—highlighted execution. Earlier data across esophageal, pancreatic, melanoma, and NSCLC trials showed favorable safety and efficacy, reinforcing platform value.
Macro biotech sentiment, J&J operational control, and institutional interest drove cumulative impact, with stock volatility reflecting trial milestones over macroeconomic pressures like rates.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots from hundreds available, which analyze and trade thousands of tickers across various strategies, timeframes, and performance metrics like win rate, profit factor, and drawdown. These curated bots, selected based on recent success and relevance, help investors automate trading with data-driven signals tailored to market conditions. Whether focusing on short-term scalping or long-term trends, users can explore, backtest, and deploy bots suited to their risk profile. Visit the page to discover leading performers and enhance your stock analysis toolkit today.
NBTX Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor upcoming data readouts from Phase 1/2 trials in NSCLC re-irradiation, pancreatic cancer, melanoma, and esophageal cancer, plus full CONVERGE progression-free survival in H1 2027 and NANORAY-312 Phase 3 results. J&J partnership milestones, including potential payments, remain critical.
Industry trends in radioenhancers and immunotherapy combinations, alongside macro factors like biotech funding and regulatory shifts, could sway sentiment. Strategic developments in the Nanoprimer platform, such as new collaborations or IP, warrant attention. Risks include trial delays, funding needs post-2028, and competitive oncology advances.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
Aroon Indicator for NBTX shows an upward move is likely
NBTX's Aroon Indicator triggered a bullish signal on May 18, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 162 similar instances where the Aroon Indicator showed a similar pattern. In of the 162 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on May 05, 2026. You may want to consider a long position or call options on NBTX as a result. In of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for NBTX just turned positive on May 05, 2026. Looking at past instances where NBTX's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
NBTX moved above its 50-day moving average on May 05, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where NBTX advanced for three days, in of 222 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for NBTX moved out of overbought territory on May 15, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
NBTX broke above its upper Bollinger Band on May 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NBTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (32.192). P/E Ratio (0.000) is within average values for comparable stocks, (49.929). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.677). Dividend Yield (0.000) settles around the average of (0.034) among similar stocks. P/S Ratio (64.516) is also within normal values, averaging (323.173).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology